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Abstract
Cancer is a public health global problem. Cyclophosphamide (CPA) 
and Doxorubicin (DOX) are used in chemotherapy, especially by gene-
rating reactive oxygen species. The clinical use of ascorbic acid during 
chemotherapy also raises several controversies due to its antagonis-
tic effects on antineoplastic agent. In this sense, this study aims to 
evaluate the effects of ascorbic acid (2 µg/mL) on the modulation 
of cytogenetic damage induced by CPA (20 µg/mL) and DOX (2 µg/
mL), as well as their interaction (AC protocol) on Sarcoma 180 tumor 
cells. Cytogenetic damage classified as apoptosis, necrosis, micronu-
clei, buds and nucleoplasmic bridges were linked to the Cytokinesis-
Block Micronucleus Assay application. CPA and DOX induce significant 
(p<0.05) increases in apoptosis, necrosis and micronuclei in the cell 
types tested. The damage on Sarcoma 180 cells was modulated by 
ascorbic acid with percentage modulation in more than 70% of CPA 
relative to apoptosis and micronuclei, and 32% to necrosis. The da-
mage of DOX has been modulated by 70% to apoptosis, 40% to ne-
crosis, rather than micronuclei, whereas, in AC protocol, modulations 
were observed by 52% to apoptosis and 32% and 40% to necrosis 
and micronuclei, respectively. There was no significance in relation to 
the nuclear buds and nucleoplasmic bridges. In addition, ascorbic acid 
did not show any effect. These results are other studies, which indicate 
hazards to chemotherapy effectiveness due to the antioxidant effects 
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Introduction
Cancer is a complex and multifactorial disease with 
epidemiological profile. Its etiology is assumed as 
genetic mutations that cause unlimited capacity of 
cell proliferation, loss of response to growth inhibi-
tion factors, evasion of apoptosis (programmed cell 
death), opportunities to invade other body tissues 
(metastases), and production of new blood vessels 
(angiogenesis) [1, 2].
The therapeutic modality for cancer treatment is 
drug therapy, such as chemotherapy. It is generally 
known for its partial selective  destruction of tumor 
cells, but causing several side effects to patients and 
damage to normal cells [3, 4]. The identification of 
the variety of responses to cancer therapy requi-
res knowledge of variables. It includes concomitant 
medications, which may alter the metabolism and 
pharmacokinetics of chemotherapy, and pointing to 
drug interactions [5, 6].
There are several therapeutic modalities for can-
cer, including the protocol associating doxorubicin 
(DOX) plus cyclophosphamide protocol (AC). The 
most common doses of these drugs are, respectively, 
60/600 (mg/m2) every 21 days [7]. Cyclophosphami-
de (CPA) is a cytotoxic agent with immuno action 
[8, 9] and alkylating to the genetic material, which 
induces apoptosis by free radicals [10, 11].
On the other hand, some researchers have de-
termined that several factors may influence cellular 
DOX toxicity, most notably the expression of the 
membrane transporter P-glycoprotein/MDR1 (P-
gp) and the generation of reactive oxygen species 
(ROS) and free radicals through the redox cycle of 
doxorubicin, as well as inhibition of topoisomerase 
II [12,13].
Most patients in chemotherapy make supple-
mentation with vitamins, especially, vitamin C, due 
to its high antioxidant capacity, which may cause 
antagonistic effects to antineoplastic and neutrali-
ze some carcinogens [14,15]. Antioxidants such as 
vitamin C compose the human diet [16], which not 
only sequester free radicals, but also regulate DNA 
repair enzymes and post-transcriptional factors [17]. 
Vitamin C (ascorbic acid), a cofactor for the alpha-
ketoglutarate dioxygenase, is important for collagen 
formation, as well as transcriptional factor, which 
regulates genes involved in tumor growth and 
apoptosis [18, 19].
In vitro studies of human MCF-7, vitamin C ex-
posure causes attenuation of antineoplastic, it may 
affect the therapeutic response [15]. There are also 
reports that indicate high doses of ascorbic acid, 
increasing apoptosis in Sarcoma 180 cells on mice 
co-treated with paclitaxel, enhancing the effects of 
anticancer [20].
However, there are numerous controversies about 
the role of antioxidant/pro-oxidant, ascorbic acid 
(AA), and its use as antioxidants during chemothe-
rapy, half-life period of antineoplastic [21-24]. Thus, 
this study aims to contribute to the understanding 
of anticancer in association with ascorbic acid in 
front of cytogenetic damage in the Sarcoma 180 
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of ascorbic acid in the modulation of oxidative stress to promote major 
cytogenetic damage that is important to tumor regression. 
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model, as well as the analysis of damage in lympho-
cytes of mice with the application of cytokinesis-
blocked micronucleus assay.
Materials and Methods
Chemicals
The antineoplastic agents, cyclophosphamide (CPA) 
and doxorubicin (DOX) were purchase from Euro-
farma® Laboratories and prepared by dilution with 
sterile 0.9% saline solution to a final concentration 
of 20 µg/mL and 2 µg/mL, respectively. The combi-
nation of both antineoplastic agents was prepared 
in the same way, keeping the same concentrations. 
The ascorbic acid (Sigma, St. Louis, MO) was solu-
bilized in 50 mM phosphate buffer (pH 7.4) till the 
final concentration of 2 µg/mL. This concentration 
was predetermined because it may not produce 
pro-oxidant effects, as reported by Putchala [25] 
and Bartel [26].
Primary culture of Sarcoma 180 cells
Cell cultures of Sarcoma 180 (S180) were perfor-
med in RPMI 1640 medium, supplemented with 
20% fetal bovine serum, 2 mM glutamine, 100 U/
mL penicillin and 100 µg/mL streptomycin, at 37ºC 
with 5% CO2. Ascite-bearing female mice bet-
ween 7 and 9 days post inoculation were sacrificed 
by cervical dislocation and a suspension of S180 
cells was harvested from the intraperitoneal cavity 
under aseptic conditions [27]. The investigational 
protocols were approved by the local Ethical Com-
mittee on Animal Research (Process No. 081/2014) 
and they are in accordance with Brazilian (COBEA 
- Colégio Brasileiro de Experimentação Animal) 
and international guidelines on the care and use 
of experimental animals (Directive 2010/63/EU of 
the European Parliament and of the Council). The 
suspension was centrifuged at 500 X g for 5 min 
to obtain a cell pellet and washed three times with 
RPMI medium. Cell concentration was adjusted to 
0.5 x 106 cells/mL in supplementing RPMI 1640 
medium flasks, and incubated with concentrations 
of the CPA (20 µg/mL), DOX (2 µg/mL) and ascor-
bic acid (2 µg/mL).
Cytokinesis-block micronucleus assay 
(CBMN)
For this study, we followed criteria for the iden-
tification of binucleate cells and CBMN assay pa-
rameters as described by Fenech [28], with some 
adaptations. Briefly, S180 cell suspension (0.5 x 
106/mL) was added in a culture flask of supple-
menting RPMI 1640 medium (20% fetal bovine 
serum), antibiotics (Sigma, St. Louis, MO) and 
phytohemagglutinin A (Gibco, Grand Island, NY). 
Each reaction flask was then  treated with antineo-
plastic agents separately, and the combination of 
both was treated in a flask marked AC treatment. 
In addition, AA was added in the co-treatment. 
Cells were incubated for 44 h at 37 ± 1 °C. After 
incubation, 6 µg/mL of cytochalasin B (Sigma, St. 
Louis, MO), they were added to the culture flask. 
Next, the flasks were returned to incubation for 
additional 28 hours. At the end of incubation pha-
ses, the cultures were transferred to Falcon tubes 
and centrifuged at 800 rpm for 5 minutes. Then, 
the supernatant was removed and the cell pellets 
were gently shaken, added 5 mL of fixative (metha-
nol: acetic acid 5:1) and 3 drops of formaldehyde, 
the tubes were centrifuged again. The procedure 
was repeated twice with a fixative solution (3:1), 
and without formaldehyde. Finally, the supernatant 
was discarded and 2 to 4 drops of cell suspension 
were dripped on slides, which were stained with 
Giemsa 5% (exposure time of 7 minutes.)
The previously coded slides were examined in 
a blind test with an optical microscope at 1000X 
magnification, considering the cytogenetic dama-
ge presented at 1000 cells per slide in duplicate. 
Nuclear division cytotoxicity index (NDCI) was cal-
culated with the equation: NDCI = (Ap + Nec + 
M1 + 2(M2) + 3(M3) + 4(M4))/N*, in which Ap 
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represents the number of apoptotic cells, Nec, the 
number of necrotic cells, M1-M4, the number of 
viable cells with 1-4 nuclei, and N*, the total num-
ber of viable and nonviable cells scored, according 
to Fenech [29].
Trypan blue exclusion test
Cell viability was analyzed by the application of 
the Trypan blue exclusion test according to Renzi 
[30]. After 72 hours of treatment with the antineo-
plastic agent, as well as untreated cells, 90 µL of 
S180 cell suspensions were removed from culture 
and added to 10 µL of Trypan Blue to different 
treatment groups: CPA, DOX and AC. Non-viable 
cells were counted by its blue color, therefore, con-
sidered as dead cells. In contrast, viable cells did not 
present this color due to their ability to expel the 
trypan blue. Cell differentiation was observed under 
an optical microscope with a magnification of 40X 
increased with Neubauer chamber’s assistance.
Cytogenetic modulatory effect of AA in 
S180 cells line
Values of percentage modulation (%M) of AA 
front cytogenetic damage induced by antineoplas-
tic agents CPA and DOX, as well as the associated 
in the AC protocol were calculated according to the 
following formula: %M = (X-(Y+AA))/X*100, which 
“X” represents the values of cytogenetic damage 
induced by antineoplastic and “Y + AA” represents 
the values of cytogenetic damage induced by anti-
neoplastic associated with AA.
Statistical analysis
For this purpose, it was used Graph Pad Prism 6.0 
(Graph pad Inc., San Diego, CA). The differences 
between groups were analyzed using one-way 
analysis of variance (ANOVA), followed by Turkey’s 
test. The calculated values  are expressed as mean ± 
standard deviation (SD) and considered statistically 
significant with p<0.05.
Results
Cell viability
S180 cell viability was performed after 72 h ex vivo 
exposure to CPA, DOX and AC. At the end, we 
applied the exclusion technique by Trypan blue. 
The treatment of S180 cells with CPA reduced cell 
viability significantly (p<0.05) compared to baseli-
ne, however, cytogenetic events were significantly 
modulated (p<0.05) by co-treatment with AA (Fi-
gure 1). Similarly, DOX also reduced cell viability 
(p<0.05), but these effects were not modulated by 
AA. Regarding the AC treatment, the results were 
consistent with the CPA that also inhibited cell via-
bility compared to baseline, but modulated by AA 
(p<0.05) (Figure 1).
Evaluation of cytogenetic damage by CPA, 
DOX and AC on S180 cells cultures, and 
the effects of AA co-treatment
The CPA, indeed, (p<0.05) induced apoptosis in S180 
cultures in relation to the untreated baseline. Howe-
ver, the CPA+AA significance (p<0.05) modulates 
Figure 1:  S180 cells exposed to antineoplastic and 
co-treated with AA. (Data represents the 
% of cell viability of 4 independent ex-
periments. CPA: cyclophosphamide (20 
µg/mL); DOX: doxorubicin (2 µg/mL); 
AC: DOX+CPA (2:20 µg/mL); AA: ascor-
bic acid (2 µg/mL). *p<0.05 compared to 
untreated cells; *a p<0.05 compared to 
CPA; *b p<0.05 compared to AC.).
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apoptosis induced by treating the cells with CPA 
(Table 1). Similarly, CPA induced significant (p<0.05) 
increases in necrosis of S180 cells, when compared 
to baseline. However, AA (2 µg/mL) has modulator 
(p<0.05) effect on the necrosis induced by CPA. 
For other cytogenetic damage, such as micronuclei, 
nuclear buds and nucleoplasmic bridges, the CPA 
significantly (p<0.05) induced the formation in S180 
cells. Nevertheless, in association with ascorbic acid, 
only micronuclei was significantly (p<0.05) modula-
ted (Table 1).
DOX also induced significantly (p<0.05) apopto-
sis and necrosis. However, it did not induce nuclear 
buds and bridges (insignificant data), but induced 
mutagenicity by the significant (p<0.05) increasing 
in micronuclei frequency. We emphasize that the 
co-treatment with DOX+AA modulated (p<0.05) 
the apoptosis and necrosis effects of DOX (Table 
1).
The CPA combination with DOX (AC protocol), 
significant (p<0.05) induced apoptosis and necrosis 
of S180 cells. However, these effects were signi-
ficantly (p<0.05) modulated by AA. Regarding to 
clastogenic and/or aneugenic effects of AC, the 
data were significant (p<0.05) for the formation of 
micronuclei and were modulated (p<0.05) by co-
treatment with AA. Similar to DOX data from the 
cytogenetic damage, the AC did not induce bridges 
and nuclear buds (insignificant data) (Table 1). 
In Figure 2, we present the overall photomicro-
graph profile of cytogenetic damage produced by 
antineoplastic, as well as co-treatment with AA. 
The cytotoxicity of antineoplastic CPA, DOX and 
AC, as well as the effects of AA co-treatment were 
evaluated by calculating the NDCI (nuclear division 
cytotoxicity index). The proportion of apoptosis and 
Figure 2:  Photomicrographic profile of effects 
produced by AA in S180 cells exposed 
to DOX, CPA and AC. (5% Giemsa stai-
ning, 100X. CPA: cyclophosphamide 20 
µg/mL. DOX: doxorubicin 2 µg/mL. AC: 
DOX+CPA (2:20 µg/mL); AA: ascorbic 
acid 2 µg/mL. AP: apoptosis. NC: necro-
sis. MN: micronuclei. BT: nuclear bud. 
PT: nucleoplasmic bridge.)
Table 1.  Cytogenetic damage induced by CPA, DOX and AC and modulatory effects of AA co-treatment 
in S180 cells line..
Treatment
Cytogenetic damages
NDCI
Apoptosis Necrosis Micronuclei Nuclear buds
Nucleoplastic 
bridges
Untreated cells 47.5 ± 7.7 39.5 ± 3.5 0.50 ± 0.7 5.5 ± 3.3 2.5 ± 0.7 0.979 ± 0.12
CPA (µg/mL) 294.5 ± 17.6a 115.0 ± 2.8a 8.5 ± 2.1a 21.5 ± 7.7a 10.5 ± 0.7a 0.716 ± 0.06a
CPA+AA (µg/mL) 76.0 ± 8.4b 77.5 ± 3.5b 2.5 ± 0.7b 26.0 ± 1.4 7.5 ± 2.8 0.813 ± 0.14b
DOX (µg/mL) 279.5 ± 28.9a 93.5 ± 3.5a 18.5 ± 4.9a 9.5 ± 3.5 5.0 ± 2.5 0.683 ± 0.05a
DOX+AA (µg/mL) 80.0 ± 2.8c 56.0 ± 4.2c 14.5 ± 2.1 8.5 ± 2.9 4.5 ± 0.7 0.748 ± 0.10c
AC (µg/mL) 568.5 ± 34.6a 85.0 ± 7.0a 20.0 ± 1.4a 8.0 ± 4.2 6.5 ± 2.1 0.380 ± 0.17a
AC+AA (µg/mL) 297.0 ± 137.2d 58.0 ± 4.2d 12.5 ± 2.2d 7.5 ± 2.5 6.0 ± 4.2 0.494 ± 0.14d
Values are mean ± standard deviation of 2000 cells evaluated. CPA: cyclophosphamide; DOX: doxorubicin; AC: doxorubicin + 
cyclophosphamide; AA: ascorbic acid. NDCI: nuclear division cytotoxicity index. ANOVA-one-way followed by Tukey's test. a: p<0.05 
comparated to untreated cells. b: p<0.05 comparated to CPA. c: p<0.05 comparated to DOX; d: p<0.05 comparated to AC.
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necrosis reflects the cellular sensitivity of the tes-
ted antitumor treatment. The CPA, DOX and AC 
showed cytotoxicity (Table 1), with the significance 
of baseline damage, but co-treatment with AA mo-
dulated the cytotoxicity induced by antineoplastic 
treatment.
Evaluation of cytogenetic modulatory 
effect of AA in S180 cells line
The data presented in Table 2 were plotted into the 
modulation percentage (%M) for cytogenetic alte-
rations of the apoptosis, necrosis, micronuclei and 
bridges induced by CPA, DOX and AC. Effectible 
ascorbic acid had modulated apoptosis induced by 
CPA with 74% (74.13 ± 0.85); however, for necrosis 
it was by 32% (32.04 ± 0.81), which indicates a 
better performance for modulating apoptosis. Simi-
larly, AA had modulated aneugenic and clastoge-
nic effects induced by CPA in S180 cells with 70% 
(70.25 ± 4.71) inhibition of micronuclei. It reports 
that the bridges induced by CPA were not modu-
lated by AA.
Effectible DOX-induced apoptosis had modulated 
by AA with more than 70% (70.25 ± 1.25) in a simi-
lar way to CPA. As observed with CPA, AA modu-
lation percentage compared to necrosis was lower 
(40%, 39.75 ± 1.25). The mutagenicity (increased 
in micronuclei) induced by DOX was not modulated 
by AA. As it was noticed in Table 2, the modulation 
percentage of cytogenetic effects induced by AC 
was lower than those observed for CPA and DOX. 
However, AA modulated about 52% (52.2 ± 7.54) 
for apoptosis, and 32% (31.9 ± 1.25) for necrosis. 
The micronuclei were modulated by 40% (39.2 ± 
4.27) with AA.
Discussion
Although the well described benefits of antioxi-
dants like ascorbic acid in the prevention of cancer, 
there are still doubts about their interference in 
chemotherapy. Antioxidants capture the superoxi-
de radical, and thus, deplete the supply of hydro-
gen peroxide intracellular, which induces cancer. 
Moreover, it causes elimination of hydroxyl radi-
cals, thus the use of antioxidants may reduce the 
effects of chemotherapy or radiation, due to the 
elimination of free radicals, since most of the ra-
diation and antitumor drugs act precisely in the 
production of free radicals to struggle against can-
cer cells [31].
To get acquainted to the action mode of an an-
titumor drug is essential for the development of 
new drugs in this line. It is believed that the antitu-
mor activity, mediated by certain drugs, can induce 
DNA damage. Thus, it may trigger the apoptosis. 
The selection is mainly based on the specific che-
motherapeutic cytotoxicity for the tumor cell type 
and relatively low toxicity to normal cells and tissues. 
However, toxicity to normal cells has a high clinical, 
particularly, when malignant cells become resistant 
to chemotherapy, which results from factors, such 
as, individual variation, tumor genetic heterogeneity 
in tumors and tumor evolution [32].
Apoptosis is a process of cellular responses to 
multiple stresses, including DNA damage, and it 
is considered as one of the bases for therapeutic 
Table 2. Cytogenetic modulatory effect of AA in 
S180 cell line.
Cytogenetic 
damage
Modulation percentage (%M) 
CPA+AA DOX+AA AC+AA
Apoptosis
74% 
(74.13 ± 0.85)
70% (
70.25 ± 1.25)
52% 
(52.2 ±7.54)
Necrosis
32% 
(32.04 ± 0.81)
40% 
(39.75 ± 1.25)
32% 
(319 ± 1.25)
Micronuclei
70% 
(70.25 ± 4.71)
NM
40% 
(39.2 ± 4.27)
Values are mean ± standard deviation. Data are presented by mo-
dulation percentage (%M) calculated with the equation: %M = (X-
(Y+AA))/X*100, where %M represents the modulation percentage 
of AA. X: represents the values of cytogenetic damage induced by 
antineoplastic (see Table 1). Y+AA: represents the values of cytoge-
netic damage induced by antineoplastic associated with ascorbic acid 
(AA). AA: ascorbic acid. CPA: cyclophosphamide; dOX: Doxorubicin. 
AC: doxorubicin + cyclophosphamide. NM: no modulation.
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response [33]. In our studies, CPA induced apop-
tosis in S180 cells (Table 1). These data point out 
the CPA action on neoplastic cells. Reactive oxygen 
species play a central role in the mechanisms invol-
ved in redox signaling and control of apoptosis in 
the cytosol and mitochondria to release cytochro-
me c, which are the initial events of apoptosis. The 
antioxidant enzymes, such as, glutathione, play a 
role in the catalytic site of the cysteine that can 
activate and inactivate caspases in the control of 
apoptosis [34].
A major goal of therapies against cancer is killing 
cancer cells. Several ways of cell death, including 
apoptosis and necrosis, can lead to the cancer cells 
death. Even with the great variability of cancer, 
studies indicate that resistance to apoptosis is one 
of the most striking features of most malignant 
tumors. The drugs used on the chemotherapy re-
sult in DNA damage and response to stress. They 
can also lead to apoptotic death in some cancer 
cells. CPA is an important antineoplastic used to 
treat cancer, because it induces a large number of 
apoptosis [35, 36], which can be related to ROS 
action [37].
However, antioxidants protect cells against DNA 
damage because they are able to sequester free 
radicals [38]. In addition, these free radicals can re-
gulate DNA in order to repair enzymes, and post-
transcriptional factors [19]. High levels of diets with 
antioxidants and/or supplementations may interfe-
re in the action of pro-oxidants chemotherapeutic 
agents [39, 40]. The combination of co-treatment of 
AA at a concentration of 2 µmol/mL with CPA, as 
well as in AC cause a modulation of the apoptosis 
induced by antineoplastic treatment in about 74% 
and 52%, respectively (Table 2).
Heaney [41] reported that in vivo ascorbic acid 
reduces the cytotoxic effects of DOX 1 mg/kg. In 
addition, ascorbic acid attenuates antineoplastic 
drug like 5-fluorouracil (150 mg/kg) induced gas-
trointestinal toxicity in rats by modulating the ex-
pression of inflammatory mediators. The inhibitory 
potential of AA may be due to the modulation of 
oxidative stress, and also activation of redox sensi-
tive transcription factor [42]. This interference was 
also observed in this study, which the apoptosis was 
reduced in CPA co-treatment with AA compared 
to a treatment with only a CPA, since this is an 
alkylating agent that induces apoptosis in rapidly 
dividing cells [43].
The results of Shatzer’s study [44], who also de-
monstrated that pharmacological concentrations of 
AA are highly antagonistic to bortezomib compa-
red to in vitro B cell positive for Epstein-Barr virus. 
Bortezomib is an inhibitor of the 26S proteasome, 
such as, CPA, thus, it shows antitumor activity in a 
variety of malignant tumor [45].
In vitro studies with human MCF-7, AA exposu-
re causes attenuation of antineoplastic activity and 
may affect the therapeutic response [15]. There are 
also reports indicating that AA can enhance the 
effectiveness of chemotherapeutic agents that can 
reduce the cytotoxicity of anticancer drugs, and also 
may prevent free radicals and neutralize some carci-
nogens [14,46,47]. The identification of the variety 
of responses to cancer therapy requires knowled-
ge of variables, including concomitant medications, 
which may alter the metabolism and pharmacokine-
tics of chemotherapy. Clinical studies showed drug 
interactions [6].
Several epidemiological studies investigating the 
effects of AA against breast cancer link many in-
consistent results, but, reports indicate that it can 
also reduce the risk of this type of cancer due to 
its antioxidant action for protection of DNA dama-
ge by neutralizing the free radicals and initiation of 
carcinogenesis [48].
DOX is one of the most effective antitumor drugs, 
but its clinical use is limited due to some adverse 
effects, such as, cardiotoxicity induced by lipid pe-
roxidation [49]. The adverse effects are caused by 
oxidative stress, but can be minimized by the use of 
antioxidants [50]. It should be reported that doxo-
rubicin induced a significant increase in apoptosis in 
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S180 cells (Table 1). However, this cytogenetic da-
mage was also modulated by AA in 70% (Table 2).
There are reports on the effect of antioxidants 
such as ascorbic acid, tocopherol and carotenoid 
that can inhibit the effects of various cytostatic 
drugs (5-fluorouracil, doxorubicin and vincristine) 
through cultures and cell lines [51, 52], which may 
reduce toxic effects in cellular systems [53].
There are many patients who are undergoing 
cancer treatments using micronutrient supplements 
to minimize side effects of the therapies. There are 
many matches on the effect of antioxidants that 
can decrease the effects of chemotherapy, but also 
mounting evidence of the antioxidant benefits at 
high concentrations, as pro-oxidants for the cyto-
toxic effects. In this context, it is important to ex-
plore the use of antioxidants and other additional 
micronutrients as an educational strategy on the 
potential beneficial and negative effects [54].
It was previously reported that ascorbic acid mo-
dulates apoptosis induction by anticancer CPA, DOX 
and AC, however, by adding apoptosis, the data 
show that antineoplastic also induce necrosis, which 
has been modulated by the AA 30% to 40% (Table 
2). Chemotherapy is usually well tolerated, never-
theless, results of treatments that induce necrosis 
are predictive of the risk for metastasize, and, this 
information can be useful for systemic therapies 
[55].
Chemotherapy-induced apoptosis involves activa-
tion of the mitochondrial death pathway, which is 
tightly regulated by the balance between pro- and 
anti-apoptotic of B-cell lymphoma 2 (Bcl-2) family 
proteins. The activation of Bcl-2 pro-apoptotic pro-
teins lead to permeability of mitochondria and re-
lease to the cytosol apoptogenic factors, such as, 
cytochrome c. The cytochrome c participates in the 
activation of caspase-9, which, in turn, activates 
effector caspases [56].
Different paths to cell death have been observed, 
including apoptosis recognized by nuclear fragmen-
tation, with activation of caspases and absence of 
inflammation; autophagy characterized by the pre-
sence of large vacuoles which induces an inflamma-
tory response; and necrosis that are not controlled, 
characterized by membrane disruption and induc-
tion of inflammatory responses [57].
In the cytogenetic damage by apoptosis and ne-
crosis, as observed in photomicrography profile in 
Figure 2, CPA, DOX and AC also induced micronu-
clei. However, ascorbic acid modulated only CPA 
(70%) and AC (42%). Yet, other cytogenetic dama-
ges like nucleoplasmic bridges were observed, but 
they have not been modulated by AA (Table 1). 
The micronuclei are formed from a whole chromo-
some or a fragment of one, and they are induced 
by genotoxic stresses, so they are closely related to 
carcinogenesis [58].
Conclusion 
Firstly, this study indicates that  the antineoplastic 
CPA, DOX and AC induce apoptosis, necrosis and 
other cytogenetic damages like micronuclei, nucleo-
plasmic bridges and nuclear buds in S180 cell line. 
Secondly, ascorbic acid can interfere with the apop-
tosis induction mechanisms and genetic aspects 
that are also clinically point to the effectiveness of 
cancer therapy.
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